Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients were able to maintain significant weight loss after switching from higher-dose injectable incretin therapies to either Foundayo or lower-dose Zepbound.

• Eli Lilly stock is showing upward bias. What should traders watch with LLY?

The company presented data from the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN studies at the 33rd European Congress on Obesity. The findings were also published in The Lancet and Nature Medicine, respectively.

SURMOUNT-MAINTAIN Meets Primary Goals

In the SURMOUNT-MAINTAIN trial, both maintenance-dose Zepbound and a reduced 5 mg dose achieved the study's primary and key secondary endpoints.

The study evaluated whether continuing Zepbound after 60 weeks of initial treatment was superior to placebo in maintaining body weight reduction through week 112.

Patients who remained on the maximum tolerated dose preserved all previously achieved weight loss. Those switched to the 5 mg dose maintained most of their reduction, regaining an average of 5.6 ...